Condition: Hepatoblastoma · Hepatocellular Carcinoma (HCC) · Liver Neoplasms · Sponsor: Eureka Therapeutics Inc.
Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.
This description comes directly from the study's public registry record.
Teresa Klask, MBA · 510-722-8719 · Teresa.Klask@eurekainc.com
Pei Wang, PhD · 510-654-7045 · Pei.Wang@eurekainc.com
Always discuss trial participation with your own doctor first.
| Children's Hospital Los Angeles | Los Angeles, California, United States | Recruiting |
| Children's Hospital Orange County | Orange, California, United States | Recruiting |
| UCSF Benioff Children's Hospitals | San Francisco, California, United States | Recruiting |
| Dana-Farber/Boston Children's Cancer and Blood Disorders Center | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04634357